Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Blood (2023) 142 (1): 44–61.

https://doi.org/10.1182/blood.2022017230

Published: 2023

Includes: Supplemental data

Journal Articles

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Blood (2023) 141 (12): 1425–1441.

https://doi.org/10.1182/blood.2022015494

Published: 2023

Includes: Supplemental data

Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Blood (2022) 139 (9): 1318–1329.

https://doi.org/10.1182/blood.2021013208

Published: 2022

Includes: Supplemental data

Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Blood (2021) 138 (7): 544–556.

https://doi.org/10.1182/blood.2020009165

Published: 2021

Includes: Supplemental data

Journal Articles

Genetic Determinants and Evolutionary History of Richter's Syndrome

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139456

Published: 2020

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136830

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Daniela Steinbrecher, PhD, Felix Seyfried, MD, Eugen Tausch, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Christof Schneider, MD

Blood (2019) 134 (Supplement_1): 1507.

https://doi.org/10.1182/blood-2019-127931

Published: 2019

Journal Articles

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, André Lechel, Sarah-Fee Katz, PhD, Eugen Tausch, Johannes Bloehdorn, MD, Daniela Steinbrecher, PhD, Vanni Torresi, Christof Schneider, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Lenhard Rudolph, Stephan Stilgenbauer

Blood (2019) 134 (Supplement_1): 1732.

https://doi.org/10.1182/blood-2019-126878

Published: 2019

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL

Viola Close, William Close, Sabrina Julia Kugler, Michaela Reichenzeller, Deyan Yordanov Yosifov, Johannes Bloehdorn, Leiling Pan, Eugen Tausch, Mike-Andrew Westhoff, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, Daniel Mertens

Blood (2019) 133 (8): 830–839.

https://doi.org/10.1182/blood-2018-09-874529

Published: 2019

Includes: Supplemental data

Journal Articles

Ibrutinib Can Induce Complete Remissions and Sustained Responses in Refractory Cutaneous or Leg-Type Diffuse Large B-Cell Lymphoma

Johannes Bloehdorn, MD, Stephanie Ellen Weissinger, MD, Anca Sindrilaru, MD, Stefan Schoensteiner, MD, Thorsten Peters, MD, Peter Moeller, MD, Ralf Marienfeld, PhD, Andreas Viardot, MD

Blood (2018) 132 (Supplement 1): 4237.

https://doi.org/10.1182/blood-2018-99-117032

Published: 2018

Journal Articles

Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL

Laura Beckmann, MD, Valeska Berg, PhD, Clarissa Dickhut, Johannes Bloehdorn, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Malte Hülsemann, MD, Stefan Loroch, Olaf Merkel, Kirsten Fischer, MD, Clemens-Martin Wendtner, Stephan Stilgenbauer, Albert Sickmann, PhD, Michael Hallek, René Zahedi, PhD, Lukas P. Frenzel, MD

Blood (2018) 132 (Supplement 1): 583.

https://doi.org/10.1182/blood-2018-99-118235

Published: 2018

Journal Articles

NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23

Viola Close, MSc, William Close, MSc, Sabrina Julia Kugler, PhD, Michaela Reichenzeller, PhD, Deyan Yordanov Yosifov, PhD, Johannes Bloehdorn, MD, Leiling Pan, MSc, Eugen Tausch, MD, Mike-Andrew Westhoff, PhD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Franz Oswald, PhD, Daniel Mertens

Blood (2018) 132 (Supplement 1): 946.

https://doi.org/10.1182/blood-2018-99-114491

Published: 2018

Journal Articles

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Johannes Bloehdorn, MD, Julia Krzykalla, MSc, Billy Michael Chelliah Jebaraj, PhD, Karlheinz Holzmann, Dr. rer. nat., Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kathryn Humphrey, Michael Wenger, Eugen Tausch, MD, Christof Schneider, MD, Lars Bullinger, MD, Kirsten Fischer, MD, Michael Hallek, MD, Daniel Mertens, Axel Benner, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1866.

https://doi.org/10.1182/blood-2018-99-116937

Published: 2018

Journal Articles

Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B.

Stephanie Ellen Weissinger, MD, Peter Moeller, MD, Ralf Marienfeld, PhD, Johannes Bloehdorn, MD, Andreas Viardot, MD

Blood (2018) 132 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2018-99-114551

Published: 2018

Journal Articles

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

Daniela Steinbrecher, MSc, Felix Seyfried, Johannes Bloehdorn, MD, Billy Michael Chelliah Jebaraj, PhD, Lüder Hinrich Meyer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Christof Schneider, MD

Blood (2018) 132 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2018-99-115845

Published: 2018

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

NARROW

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

MARCKS affects cell motility and response to BTK inhibitors in CLL

Genetic Determinants and Evolutionary History of Richter's Syndrome

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL

Ibrutinib Can Induce Complete Remissions and Sustained Responses in Refractory Cutaneous or Leg-Type Diffuse Large B-Cell Lymphoma

Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL

NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23

MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy

Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B.

Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Postibrutinib outcomes in patients with mantle cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only